Sugi Predict

Sugi Predict / Compounds / SCHEMBL130736

SCHEMBL130736

SCHEMBL130736

COc1cc(N)cc(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPT P10636 2/20 0.44
▸ KDM1A O60341 1/20 0.43
▸ MAPK1 P28482 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ RXRG P48443 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41
▸ KRAS P01116 1/20 0.40
▸ SOS1 Q07889 1/20 0.40
▸ NR2E1 Q9Y466 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30448494 1.00 L3MBTL1 (0.45) L3MBTL1RAB9AALDH1A1MAPTKDM1A
SCHEMBL8199949 0.87 HDAC3 (0.42) L3MBTL1RAB9AMAPTKDM1AKRAS
SCHEMBL5782136 0.84 ALDH1A1 (0.58) L3MBTL1RAB9AALDH1A1MAPTKDM1A
SCHEMBL679095 0.84 ALDH1A1 (0.50) L3MBTL1RAB9AALDH1A1MAPTKDM1A
SCHEMBL7186658 0.83 ALDH1A1 (0.47) L3MBTL1RAB9AALDH1A1MAPTMAPK1
Hydrochloric Acid SCHEMBL8952497 0.81 ALDH1A1 (0.45) L3MBTL1RAB9AALDH1A1MAPTMAPK1
SCHEMBL1100543 0.81 MAPT (0.50) L3MBTL1RAB9AALDH1A1MAPTMAPK1
SCHEMBL5866793 0.80 MAPT (0.50) L3MBTL1RAB9AALDH1A1MAPTKDM1A
SCHEMBL6846413 0.79 ALDH1A1 (0.44) RAB9AALDH1A1MAPTMAPK1CYP3A4
SCHEMBL21893893 0.79 ALDH1A1 (0.44) L3MBTL1RAB9AALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100166765-A1 BENZOQUINAZOLINE DERIVATIVES NOVARTIS AG (CH) 2010-07-01 — — US claimed
EP-1917246-B1 BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS NOVARTIS AG (CH) 2009-11-11 — — EP claimed
EP-1917246-A1 BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS Novartis AG (CH) 2008-05-07 — — EP claimed
WO-2007020046-A1 BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS NOVARTIS AG (CH) 2007-02-22 — — WO claimed
US-5354495-A Homo- or copolymerizable through ethylenic unsaturation NIPPON PAINT CO., LTD. (JP) 1994-10-11 — — US claimed
EP-0177122-B1 ACRYLAMIDE DERIVATIVES Nippon Paint Co., Ltd. (JP) 1992-04-01 — — EP claimed
US-4935413-A ELASTICITY, ADHESION AND DISPERSIBILITY NIPPON PAINT CO., LTD. (JP) 1990-06-19 — — US claimed
US-12545654-B2 MYC inhibitors and uses thereof STEMSYNERGY THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20250353853-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-11-20 — — US disclosed
US-12338226-B2 Substituted benzodiazoles and use thereof in therapy THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) 2025-06-24 — — US disclosed
EP-4532476-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-04-09 — — EP disclosed
US-20240287020-A1 SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2024-08-29 — — US disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 — — US disclosed
US-5089513-A Antiinflammatory agents; antiallergens; asthma; side effect reduction ICI PHARMA (FR) 1992-02-18 — — US disclosed
US-4935413-A ELASTICITY, ADHESION AND DISPERSIBILITY NIPPON PAINT CO., LTD. (JP) 1990-06-19 — — US disclosed
US-4882354-A N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents NORWICH EATON PHARMACEUTICALS, INC. (US) 1989-11-21 — — US disclosed
EP-0321431-A1 N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents Norwich Eaton Pharmaceuticals, Inc. (US) 1989-06-21 — — EP disclosed
EP-0207621-A2 Functional polymers and their production Nippon Paint Co., Ltd. (JP) 1987-01-07 — — EP disclosed
EP-0177122-A2 Acrylamide derivatives Nippon Paint Co., Ltd. (JP) 1986-04-09 — — EP disclosed
US-4058642-A HYPERTENSIVE BOEHRINGER INGELHEIM GMBH (DT) 1977-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100166765-A1 BENZOQUINAZOLINE DERIVATIVES CACNA1A, BMP4, TPX2 L3MBTL1 1697/4885RAB9A 395/4885ALDH1A1 3966/4885
US-20240287020-A1 SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY XDH, CYP11B2, CYP4X1 L3MBTL1 2150/4885RAB9A 2948/4885ALDH1A1 274/4885
US-20250353853-A1 FLAVIVIRUS INHIBITORS SPINT2, EIF2AK2, DDX5 L3MBTL1 2177/4885RAB9A 773/4885ALDH1A1 3259/4885
US-12545654-B2 MYC inhibitors and uses thereof MYC, MYCBP, NR2E1 L3MBTL1 2048/4885RAB9A 2848/4885ALDH1A1 4317/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 L3MBTL1 2136/4885RAB9A 776/4885ALDH1A1 4277/4885
US-12338226-B2 Substituted benzodiazoles and use thereof in therapy XDH, CYP11B2, CYP4X1 L3MBTL1 2150/4885RAB9A 2948/4885ALDH1A1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.